CLLS - Cellectis SA - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CLLS is currently covered by 3 analysts with an average price target of $16.49. This is a potential upside of $13.83 (519.92%) from yesterday's end of day stock price of $2.66.

Cellectis SA's activity chart (see below) currently has 26 price targets and 33 ratings on display. The stock rating distribution of CLLS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 25% with an average time for these price targets to be met of 25.78 days.

Highest price target for CLLS is $4, Lowest price target is $4, average price target is $6.67.

Most recent stock forecast was given by GENA WANG from BARCLAYS on 13-May-2025. First documented stock forecast 16-Sep-2015.

Currently out of the existing stock ratings of CLLS, 5 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$4

$1.49 (59.36%)

$5

2 months 26 days ago
(13-May-2025)

0/4 (0%)

$2.59 (183.69%)

Buy

$10

$7.49 (298.41%)

1 years 1 months 27 days ago
(12-Jun-2024)

0/3 (0%)

$7.58 (313.22%)

Buy

$6

$3.49 (139.04%)

$6

1 years 2 months 8 days ago
(31-May-2024)

0/6 (0%)

$3.29 (121.40%)

Buy

2 years 4 months 3 days ago
(05-Apr-2023)

4/4 (100%)

$15.39 (87.39%)

209

Buy

$10

$7.49 (298.41%)

$10

3 years 2 months 21 days ago
(18-May-2022)

3/4 (75%)

$6.73 (205.81%)

17

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CLLS (Cellectis SA) average time for price targets to be met?

On average it took 25.78 days on average for the stock forecasts to be realized with a an average price target met ratio 25

Which analyst has the current highest performing score on CLLS (Cellectis SA) with a proven track record?

YIGAL NOCHOMOVITZ

Which analyst has the current lower performing score on CLLS (Cellectis SA) with a proven track record?

WANGZHI LI

Which analyst has the most public recommendations on CLLS (Cellectis SA)?

Yigal Nochomovitz works at CITI and has 24 price targets and 15 ratings on CLLS

Which analyst is the currently most bullish on CLLS (Cellectis SA)?

Christopher Marai with highest potential upside - $70.49

Which analyst is the currently most reserved on CLLS (Cellectis SA)?

Yigal Nochomovitz with lowest potential downside - -$0

Cellectis SA in the News

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights07/31/2025100,325,22989,428,630 About Cellectis    Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) NEW YORK, 07 août 2025 (GLOBE NEWSWIRE) — Place de cotation : Euronext Growth Code ISIN : FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/07/2025100 325 22989 428 630 À propos de Cellectis            Cellectis est une société de biotechnologie au...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?